ClinicalTrials.gg

Program

praliciguat

Also written as “IW-1973”, “Praliciguat (Part A)” and “Praliciguat (Part B)”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Glomerulosclerosis, Focal Segmental · Heart Failure, led by 2 companies.

Furthest: phase 2, since Sep 15, 20168 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ironwood Pharmaceuticals50 open or runningphase 2since Sep 15, 2016Oct 29, 2015none ahead
Akebia Therapeutics31 open or runningphase 2since Jul 12, 2017Jul 12, 2017Jun 2027phase 2 · NCT07268638

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2015First study: phase 1 study in HealthyNew to Ironwood PharmaceuticalsIronwood Pharmaceuticals · NCT02616861 · 54 enrolled · United States
  2. Sep 15, 2016Phase 2 study in Diabetes Mellitus, Type 2Ironwood Pharmaceuticals · NCT02906579 · 11 enrolled · United States
  3. Mar 8, 2017Phase 2 study in Diabetes Mellitus, Type 2Ironwood Pharmaceuticals · NCT03091920 · 26 enrolled · United States
  4. Jul 12, 2017Akebia Therapeutics's first study: phase 2 study in Type 2 Diabetes Mellitus With Diabetic NephropathyNew to Akebia TherapeuticsAkebia Therapeutics · NCT03217591 · 156 enrolled · United States
  5. Aug 16, 2017Phase 2 study in Heart FailureAkebia Therapeutics · NCT03254485 · 196 enrolled · United States, Canada
  6. Apr 9, 2018Phase 1 study in HealthyIronwood Pharmaceuticals · NCT03499106 · 24 enrolled · United States
  7. Jan 24, 2019Phase 1 study in Healthy VolunteersIronwood Pharmaceuticals · NCT03818295 · 8 enrolled · United States
  8. Nov 26, 2025Phase 2 study in Glomerulosclerosis, Focal SegmentalAkebia Therapeutics · NCT07268638 · 60 planned · United States

Ahead

  1. Jun 2027Primary completion: phase 2 study in Glomerulosclerosis, Focal SegmentalAkebia Therapeutics · NCT07268638

TargetBeta

“Soluble guanylate cyclase activator”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
Nitroglycerinrulemediquest-therapeuticsphase 414
ataciguatruleSanofiphase 33

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07268638Glomerulosclerosis, Focal Segmental · United States2RecruitingAkebia TherapeuticsJun 202760
NCT03818295Healthy Volunteers · United States1CompletedIronwood PharmaceuticalsApr 24, 20198
NCT03499106Healthy · United States1CompletedIronwood PharmaceuticalsJul 6, 201824
NCT03254485Heart Failure · United States, Canada2CompletedAkebia TherapeuticsAug 19, 2019196
NCT03217591Type 2 Diabetes Mellitus With Diabetic Nephropathy · United States2CompletedAkebia TherapeuticsAug 20, 2019156
NCT03091920Diabetes Mellitus, Type 2 · United States2CompletedIronwood PharmaceuticalsAug 3, 201726
NCT02906579Diabetes Mellitus, Type 2 · United States2CompletedIronwood PharmaceuticalsMar 17, 201711
NCT02616861Healthy · United States1CompletedIronwood PharmaceuticalsMay 201654

How it is read

Names in the registry

  • “IW-1973”, 7 entries
  • “Praliciguat (Part A)”, 1 entry
  • “Praliciguat (Part B)”, 1 entry
  • “[14C]-praliciguat”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.